GeoVax Labs, a biotechnology company developing innovative immunotherapies, is set to share significant clinical research at two prominent medical conferences in April 2025. The presentations will focus on the company's COVID-19 vaccine candidate GEO-CM04S1 and its oncology-focused gene-directed therapy Gedeptin.
At the World Vaccine Congress in Washington, DC, Dr. Don J. Diamond from City of Hope Comprehensive Cancer Center will present Phase 2b study results comparing GeoVax's multi-antigen COVID-19 vaccine candidate to currently approved vaccines. This research is particularly significant for immunocompromised patients who may have limited protection from existing COVID-19 vaccines.
The American Association of Cancer Research conference in Chicago will feature a presentation by Dr. J. Marc Pipas on Gedeptin, a viral-vectored gene-directed prodrug therapy targeting solid tumors. The research represents a potential breakthrough in treating hard-to-address cancer types, specifically focusing on needle-accessible solid tumors.
These presentations underscore GeoVax's commitment to developing innovative therapies for complex medical challenges. The company's research spans critical areas including COVID-19 vaccine development for vulnerable populations and novel cancer treatment approaches, potentially offering new hope for patients with limited existing treatment options.
